Results 21 to 30 of about 177,775 (151)

Immune Checkpoint Inhibitors in Melanoma [PDF]

Melanoma Management, 2015
The potential to harness the power of the immune system and effectively treat patients with metastatic melanoma is finally being realized with the advent of immune checkpoint inhibitors. These new therapies herald a new era in the treatment of melanoma with the potential to produce very durable responses and possible cure for a subset of patients ...
Adam J, Cooper, Matteo S, Carlino, Richard F, Kefford   +2 more
openaire   +2 more sources

Challenges of Immune Checkpoint Inhibitors in Treatment of Non-small Cell Lung Cancer

Zhongliu Fangzhi Yanjiu, 2019
With the gradually in-depth research of immune checkpoint, the checkpoint inhibitors, such as programmed death-1(PD-1) inhibitors, programmed death–ligand 1(PD-L1) inhibitors and cytotoxic T lymphocyte-associated protein-4(CTLA-4) inhibitors, had made ...
LI Xiangmin, FAN Zaiwen
doaj   +1 more source

Histone Deacetylase Inhibitors to Overcome Resistance to Targeted and Immuno Therapy in Metastatic Melanoma

Frontiers in Cell and Developmental Biology, 2020
Therapies that target oncogenes and immune checkpoint molecules constitute a major group of treatments for metastatic melanoma. A mutation in BRAF (BRAF V600E) affects various signaling pathways, including mitogen activated protein kinase (MAPK) and PI3K/
Minjeong Yeon, Youngmi Kim, Hyun Suk Jung, Dooil Jeoung   +3 more
doaj   +1 more source

Fueling the engine and releasing the break: combinational therapy of cancer vaccines and immune checkpoint inhibitors

Cancer Biology & Medicine, 2015
Immune checkpoint inhibitors are increasingly drawing much attention in the therapeutic development for cancer treatment. However, many cancer patients do not respond to treatments with immune checkpoint inhibitors, partly because of the lack of tumor ...
Jennifer Kleponis, Richard Skelton, Lei Zheng   +2 more
doaj   +1 more source

Research Progress on Cardiotoxicity of PD-1/PD-L1 Immune Checkpoint Inhibitors

Zhongliu Fangzhi Yanjiu, 2021
Cardiotoxicity is a serious complication of antineoplastic drugs. With the continuous development of antineoplastic drugs, immune checkpoint inhibitors have been used in the treatment of a variety of cancers.
YU Lin, LI Guangping, ZHOU Changyu, FU Huaying   +3 more
doaj   +1 more source

Current Clinical Applications and Future Perspectives of Immune Checkpoint Inhibitors in Non-Hodgkin Lymphoma

Journal of Immunology Research, 2020
Cancer cells escape immune recognition by exploiting the programmed cell-death protein 1 (PD-1)/programmed cell-death 1 ligand 1 (PD-L1) immune checkpoint axis.
John Apostolidis, Ayman Sayyed, Mohammed Darweesh, Panayotis Kaloyannidis, Hani Al Hashmi   +4 more
doaj   +1 more source

Immune Checkpoint Inhibitor-Induced Central Diabetes Insipidus: Looking for the Needle in the Haystack or a Very Rare Side-Effect to Promptly Diagnose?

Frontiers in Oncology, 2022
Immune checkpoint inhibitors have improved the survival in patients affected by an increasing number of malignancies, but they may also trigger various autoimmune side-effects, including endocrinopathies.
Agnese Barnabei, Lidia Strigari, Andrea Corsello, Rosa Maria Paragliola, Luca Falzone, Roberto Salvatori, Salvatore Maria Corsello, Salvatore Maria Corsello, Francesco Torino   +8 more
doaj   +1 more source

Development of Extragenital Lichen Sclerosus in Malignant Melanoma Patients Treated With Ipilimumab in Combination With Nivolumab

Frontiers in Oncology, 2020
The immune checkpoint inhibitors opened a new era for the treatment of melanoma. Nowadays, combined immune checkpoint inhibitors are administered to provide additive or synergistic effects on anti-melanoma immunity.
S. Morteza Seyed Jafari, Laurence Feldmeyer, Robert E. Hunger   +2 more
doaj   +1 more source

Emerging dynamics pathways of response and resistance to PD-1 and CTLA-4 blockade: tackling uncertainty by confronting complexity

Journal of Experimental & Clinical Cancer Research, 2021
Immune checkpoint inhibitors provide considerable therapeutic benefit in a range of solid cancers as well as in a subgroup of hematological malignancies.
Allan Relecom, Maysaloun Merhi, Varghese Inchakalody, Shahab Uddin, Darawan Rinchai, Davide Bedognetti, Said Dermime   +6 more
doaj   +1 more source

The role of immune checkpoint inhibitors in the development and treatment of infectious processes [PDF]

Клиническая практика
The incidence and prevalence of oncological diseases, which are the second most frequent cause of death, is steadily increasing among the population of the Russian Federation.
Dilya A. Mustafina, Aisylu N. Bagautdinova, Milyausha M. Zinatullina, NIkita A. Gorbunov, Elvina T. Zainetdinova, Diana I. Bukharmetova, Daniil Yu. Leonov, Aibike G. Pirmagomedova, Anna E. Chernyshova, Maria P. Markhanos, Anna G. Abgaryan, Arina S. Arustamyan, Konstantin S. Chavro, Farzonakhon Mirzojonova   +13 more
doaj   +1 more source